We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01918579
Previous Study | Return to List | Next Study

C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting (CRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01918579
Recruitment Status : Completed
First Posted : August 7, 2013
Last Update Posted : November 15, 2016
National Hospital for Tropical Diseases, Hanoi, Vietnam
Information provided by (Responsible Party):
Oxford University Clinical Research Unit, Vietnam

Brief Summary:

Many studies have showed that rapid point-of-care (POC) c-reactive protein (CRP) test can reduce inappropriate use of antibiotic at primary health care level. In Vietnam, prevalence of antibiotic abuse for community acute respiratory infection has been reported. This study will test the hypothesis that CRP POC testing for patients with non-severe acute respiratory illness at primary healthcare stations reduces inappropriate antibiotic use safely.

The study will be conducted at ten district health care facilities in Hanoi, Viet Nam. Investigators intend to enroll 2,000 participants aged 6-65 years with non-severe acute respiratory infection. Patients will be randomly allocated to the control or the intervention arm. Participants in the control group will be treated according to routine care. Participants in the intervention arm will have a CRP test, the results of which will be available to the health care practitioner to contribute to their diagnosis and treatment decisions.

All patients will be followed-up via telephone call after 14 days. The study will compare the proportion of patients in each arm receiving any antibiotics within 2 weeks of study enrollment.

Condition or disease Intervention/treatment Phase
Acute Respiratory Infections Procedure: Patients will be tested by rapid POC CRP test Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2037 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Efficacy of Point-of-care (POC) C-reactive Protein Testing to Reduce Inappropriate Use of Antibiotics for Acute Respiratory Infections (ARIs) in the Primary Health Care Setting of Hanoi - a Randomized Controlled Trial
Study Start Date : March 2014
Actual Primary Completion Date : July 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
Experimental: CRP intervention
Patients will be tested by rapid POC CRP test
Procedure: Patients will be tested by rapid POC CRP test
Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.

No Intervention: Control
Patients will not be tested by rapid POC CRP test

Primary Outcome Measures :
  1. Proportion of patients receiving any antibiotic [ Time Frame: 2 weeks ]
    Number of patients receiving any antibiotic within 2 weeks of study enrollment as a proportion of the total number of patients.

Secondary Outcome Measures :
  1. Duration of symptoms [ Time Frame: 2 weeks ]
    Number of days that symptoms (including fever or any respiratory symptom) endure.

  2. Frequency of re-consultation [ Time Frame: 2 weeks ]
    Number of visits to a health care practitioner during the 14 day follow-up.

  3. Frequency of serious adverse events [ Time Frame: 2 weeks ]
    Number of serious adverse events which occur during the 14 day follow-up period.

Other Outcome Measures:
  1. The attitudes and satisfaction of patients and health center staff towards the test. [ Time Frame: 2 weeks ]

    Patients and health center staff will be interviewed by structured questionnaire to assess their attitudes and satisfaction toward the intervention.

    The Likert scale will be used for quantifying attitude orientation of interviewees

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients, aged 6 to 65 years, that visit one of the 10 selected primary healthcare centers
  • Suspected to have acute respiratory tract infection (ARI) by treating physician
  • Informed consent

Exclusion Criteria:

  • Severe respiratory disease as determined by treating doctor
  • Any disease or symptom requiring hospital referral as determined by treating doctor
  • Immunosuppressed patients (e.g. HIV, long term steroid use)
  • Suspicion of tuberculosis
  • Evidence of acute or chronic liver disease (e.g. hepatitis or cirrhosis due to any cause)
  • Past medical history of: neoplastic disease, congestive cardiac failure, chronic obstructive pulmonary disease, insulin-dependent diabetes or renal disease
  • Pregnancy
  • No access to telephone
  • Not able to come for follow up visit on day 3 or 4.
  • Already taking antibiotics at the time of presentation
  • Symptoms present for more than 2 weeks
  • Presence of any sign of severe diseases as defined by the British Thoracic Society modified CRP-65 system for severity scoring of pneumonia in primary care.

For children (Age ≥ 6 years and < 16 years) additional exclusion criteria include: Tachypnea, signs of chest wall in drawing, reduced consciousness, confusion, dehydration, hypothermia, severe malnutrition, unable to feed or drink, vomiting, and convulsions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01918579

Layout table for location information
National Hospital for Tropical Diseases
Hanoi, Vietnam, 10000
Sponsors and Collaborators
Oxford University Clinical Research Unit, Vietnam
National Hospital for Tropical Diseases, Hanoi, Vietnam
Layout table for investigator information
Study Director: Heiman FL Wertheim, M.D,Ph.D Oxford University Clinical Research Unit
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oxford University Clinical Research Unit, Vietnam
ClinicalTrials.gov Identifier: NCT01918579    
Other Study ID Numbers: 05HN
First Posted: August 7, 2013    Key Record Dates
Last Update Posted: November 15, 2016
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Respiratory Tract Diseases